Skip to main content
SpringerLink
Log in

Potential Cardiac Applications of Phosphodiesterase Type-5 Inhibition

  • Chapter
Heart Disease and Erectile Dysfunction

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

The risk factors associated with erectile dysfunction (ED) overlap extensively with risk factors associated with cardiovascular disease and include age, diabetes, hypertension, smoking, and hypercholesterolemia (1,2). This suggests a common pathophysiological basis that is likely to be the vascular endothelium and the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway. ED is more prevalent and severe in patients with hypertension than in the general population (3) and can be a predictor of cardiovascular disease (1,4).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61.

    PubMed  CAS  Google Scholar 

  2. McVary KT, Carrier S, Wessells H. Smoking and erectile dysfunction: evidence based analysis. J Urol 2001;166:1624–1632.

    Article  PubMed  CAS  Google Scholar 

  3. Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000;164:1188–1191.

    Article  PubMed  CAS  Google Scholar 

  4. Burchardt M, Burchardt T, Anastasiadis AG, et al. Erectile dysfunction is a marker for cardiovascular complications and psychological functioning in men with hypertension. Int J Impot Res 2001;13:276–281.

    Article  PubMed  CAS  Google Scholar 

  5. Dzau VJ, Gibbons GH, Mann M, et al. Future horizons in cardiovascular molecular therapeutics. Am J Cardiol 1997;80(Suppl 9A):331–391.

    Google Scholar 

  6. Alberts GF, Peifley KA, Johns A, et al. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem 1994;269:10112–10118.

    PubMed  CAS  Google Scholar 

  7. de Nucci G, Thomas R, D’Orleans-Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988;85:9797–9800.

    Article  PubMed  Google Scholar 

  8. Pudda P, Pudda GM, Zaca F, et al. Endothelial dysfunction in hypertension. Acta Cardiol 2000;55:221–232.

    Article  Google Scholar 

  9. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999;31:61–74.

    Article  PubMed  CAS  Google Scholar 

  10. Holness W, Santore TA, Brown GP, et al. Expression of Q227L-Galpha(s) inhibits intimai vessel wall hyperplasia after balloon injury. Proc Natl Acad Sci USA 2001;98:1288–1293.

    Article  PubMed  CAS  Google Scholar 

  11. Davies MG, Mason DP, Tran PK, et al. G-protein expression and intimai hyperplasia after arterial injury: a role for Galpha(i) proteins. J Vasc Surg 2001;33: 408–418.

    Article  PubMed  CAS  Google Scholar 

  12. John S, Schmieder RE. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens 2000; 18:363–374.

    Article  PubMed  CAS  Google Scholar 

  13. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109–142.

    PubMed  CAS  Google Scholar 

  14. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med 1998;338:520–531.

    Article  PubMed  CAS  Google Scholar 

  15. American Academy of Pediatrics. Committee on Fetus and Newborn. Use of inhaled nitric oxide. Pediatrics 2000;106:344–345.

    Article  Google Scholar 

  16. Hayward CS, Macdonald PS, Keogh AM. Inhaled nitric oxide in cardiology. Expert Opin Invest Drugs 2001;10:1947–1956.

    Article  CAS  Google Scholar 

  17. Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:5–16.

    Article  PubMed  CAS  Google Scholar 

  18. Ballard SA, Gingell CJ, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998;159:2164–2171.

    Article  PubMed  CAS  Google Scholar 

  19. Jackson G, Benjamin N, Jackson N, et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999;83(Suppl 5A):13C–20C.

    PubMed  Google Scholar 

  20. Zusman RM, Morales A, Glasser DB, et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999;83(Suppl 5A):35C–44C.

    Article  PubMed  CAS  Google Scholar 

  21. Campbell SF. Science, art and drug discovery: a personal perspective. Clin Sci (Lond) 2000;99:255–260.

    Article  CAS  Google Scholar 

  22. de Wit C, Bolz SS, Pohl U. Interaction of endothelial autacoids in microvascular control. Z Kardiol 2000;89(Suppl 9):IX/113–116.

    Google Scholar 

  23. Valiance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989;2:997–1000.

    Article  Google Scholar 

  24. Haynes WG, Noon JP, Walker BR, et al. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 1993;11:1375–1380.

    Article  PubMed  CAS  Google Scholar 

  25. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989;86: 3375–3378.

    Article  PubMed  CAS  Google Scholar 

  26. Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans. Am J Physiol 1996;270:F845–F851.

    PubMed  CAS  Google Scholar 

  27. Katz SD, Biasucci L, Sabba C, et al. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol 1992;19:918–925.

    Article  PubMed  CAS  Google Scholar 

  28. Desouza C, Parulkar A, Lumpkin D, et al. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002;25:1336–1339.

    Article  PubMed  CAS  Google Scholar 

  29. Katz SD, Balidemaj K, Homma S, et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36:845–851.

    Article  PubMed  CAS  Google Scholar 

  30. Dishy V, Sofowora G, Harris PA, et al. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clin Pharmacol Ther 2001;70:270–279.

    Article  PubMed  CAS  Google Scholar 

  31. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60–68.

    Article  PubMed  Google Scholar 

  32. Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995;270: 14214–14219.

    Article  PubMed  CAS  Google Scholar 

  33. Peng HB, Rajavashisth TB, Libby P, et al. Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J Biol Chem 1995;270:17050–17055.

    Article  PubMed  CAS  Google Scholar 

  34. Ohara Y, Peterson TE, Sayegh HS, et al. Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation 1995;92:898–903.

    Article  PubMed  CAS  Google Scholar 

  35. Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001;104:376–379.

    Article  PubMed  CAS  Google Scholar 

  36. Dobrucki LW, Kalinowski L, Dobrucki IT, et al. Statin-stimulated nitric oxide release from endothelium. Med Sci Monit 2001;7:622–627.

    PubMed  CAS  Google Scholar 

  37. Kalinowski L, Dobrucki LW, Brovkovych V, et al. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 2002;105:933–938.

    Article  PubMed  CAS  Google Scholar 

  38. Mehta JL, Li DY, Chen HJ, et al. Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun 2001;289:857–861.

    Article  PubMed  CAS  Google Scholar 

  39. Li H, Lewis A, Brodsky S, et al. Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme a reductase in vascular endothelial cells: a mechanism for development of atherosclerosis? Circulation 2002;105:1037–1043.

    Article  PubMed  CAS  Google Scholar 

  40. Vlachopoulos C, Hirata K, O’Rourke M. Effects of sildenafil (Viagra®) on wave reflection: a new insight into its cardiovascular effects. J Am Coll Cardiol 2001; 37(Suppl A):260A.

    Google Scholar 

  41. Vlachopoulos C, O’Rourke MF, Hirata K. Sildenafil (Viagra®) improves the elastic properties of the aorta. Am J Hypertens 2001;14:6A.

    Google Scholar 

  42. Mahmud A, Hennessy M, Feely J. Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens 2001;15: 707–713.

    Article  PubMed  CAS  Google Scholar 

  43. Jones SP, Girod WG, Palazzo AJ, et al. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am J Physiol 1999;276:H1567–H1573.

    PubMed  CAS  Google Scholar 

  44. Massberg S, Sausbier M, Klatt P, et al. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3’,5’-monophosphate kinase I. J Exp Med 1999;189:1255–1264.

    Article  PubMed  CAS  Google Scholar 

  45. Adrie C, Bloch KD, Moreno PR, et al. Inhaled nitric oxide increases coronary artery patency after thrombolysis. Circulation 1996;94:1919–1926.

    Article  PubMed  CAS  Google Scholar 

  46. Fox-Robichaud A, Payne D, Hasan SU, et al. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J Clin Invest 1998;101:2497–2505.

    Article  CAS  Google Scholar 

  47. Ockaili R, Salloum F, Hawkins J, et al. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial KATP channels in rabbits. Am J Physiol Heart Circ Physiol 2002;283:H1263–H1269.

    PubMed  CAS  Google Scholar 

  48. Hare JM, Colucci WS. Role of nitric oxide in the regulation of myocardial function. Prog Cardiovasc Dis 1995;38:155–166.

    Article  PubMed  CAS  Google Scholar 

  49. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res 1996;79:363–380.

    Article  PubMed  CAS  Google Scholar 

  50. Ishida H, Ichimori K, Hirota Y, et al. Peroxynitrite-induced cardiac myocyte injury. Free Radic Biol Med 1996;20:343–350.

    Article  PubMed  CAS  Google Scholar 

  51. Nakamura M. Peripheral vascular remodeling in chronic heart failure: clinical relevance and new conceptualization of its mechanisms. J Card Fail 1999;5: 127–138.

    Article  PubMed  CAS  Google Scholar 

  52. Driss AB, Devaux C, Henrion D, et al. Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure. Circulation 2000;101:2764–2770.

    Article  PubMed  Google Scholar 

  53. Bauersachs J, Bouloumie A, Fraccarollo D, et al. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 1999;100:292–298.

    Article  PubMed  CAS  Google Scholar 

  54. Sakuma I, Akaishi Y, Tomioka H, et al. Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery. Eur J Pharmacol 2002; 437:155–163.

    Article  PubMed  CAS  Google Scholar 

  55. Negrao CE, Hamilton MA, Fonarow GC, et al. Impaired endothelium-mediated vasodilation is not the principal cause of vasoconstriction in heart failure. Am J Physiol Heart Circ Physiol 2000;278:H168–H174.

    PubMed  CAS  Google Scholar 

  56. Webb DJ, Freestone S, Allen MJ, et al. Sildenafil citrate and blood-pressurelowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999;83(Suppl 5A):21C–28C.

    Article  PubMed  CAS  Google Scholar 

  57. Vardi Y, Klein L, Nassar S, et al. Effects of sildenafil citrate (Viagra) on blood pressure in normotensive and hypertensive men. Urology 2002;59:747–752.

    Article  PubMed  Google Scholar 

  58. Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83(Suppl 5A):3C–12C.

    Article  PubMed  CAS  Google Scholar 

  59. Burslem F, Ellis P. Sildenafil enhances the platelet antiaggregatory activity of nitric oxide. Abstract LB11. Presented at: The American Society for Biochemistry and Molecular Biology and The American Society for Pharmacology and Experimental Therapeutics (ASBMB/ASPET) Joint Meeting; June 7, 2000; Boston, MA.

    Google Scholar 

  60. Rehse K, Scheffler H, Reitner N. Interaction of Viagra with the NO donors molsidonúne and RE 2047 with regard to antithrombotic and blood pressure lowering activities. Arch Pharm (Weinheim) 1999;332:182–184.

    Article  CAS  Google Scholar 

  61. Berkels R, Klotz T, Sticht G, et al. Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. J Cardiovasc Pharmacol 2001; 37:413–421.

    Article  PubMed  CAS  Google Scholar 

  62. Hirose R, Okumura H, Yoshimatsu A, et al. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5. Eur J Pharmacol 2001;431: 17–24.

    Article  PubMed  CAS  Google Scholar 

  63. Schmidt U, Han RO, DiSalvo TG, et al. Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition. J Am Coll Cardiol 2001;37:1981–1988.

    Article  PubMed  CAS  Google Scholar 

  64. Przyklenk K, Kloner RA. Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. J Am Coll Cardiol 2001;37:286–292.

    Article  PubMed  CAS  Google Scholar 

  65. Chen Y, Du R, Traverse JH, et al. Effect of sildenafil on coronary active and reactive hyperemia. Am J Physiol Heart Circ Physiol 2000;279:H2319–H2325.

    PubMed  CAS  Google Scholar 

  66. Ishikura F, Beppu S, Hamada T, et al. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation 2000;102:2516–2521.

    Article  PubMed  CAS  Google Scholar 

  67. Traverse JH, Chen YJ, Du R, et al. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. Circulation 2000;102:2997–3002.

    Article  PubMed  CAS  Google Scholar 

  68. Herrmann HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342:1622–1626.

    Article  PubMed  CAS  Google Scholar 

  69. Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000;36:25–31.

    Article  PubMed  CAS  Google Scholar 

  70. Jackson G, Keltai M, Csanady M, et al. Sildenafil has mild nitrate-like hemodynamic effects in patients with coronary artery disease and erectile dysfunction (abst). Presented at: American College of Cardiology, Chicago, IL; March 30-April 2 2003;

    Google Scholar 

  71. Halcox JPJ, Nour KRA, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002;40:1232–1240.

    Article  PubMed  CAS  Google Scholar 

  72. Oliver JJ, Bell K, Leckie SM, et al. Interaction between glyceryl trinitrate and sildenafil citrate (Viagra) may last less than four hours. Presented at: 10th World Congress of the International Society for Sexual and Impotence Research; September 22–26, 2002, 2002; Montreal, Canada.

    Google Scholar 

  73. Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002;287:719–725.

    Article  PubMed  CAS  Google Scholar 

  74. Patrizi R, Leonardo F, Pelliccia F, et al. Effect of sildenafil citrate upon myocardial ischemia in patients with chronic stable angina in therapy with beta-blockers. Ital Heart J 2001;2:841–844.

    PubMed  CAS  Google Scholar 

  75. Fox KM, Thadani U, Ma PTS, et al. Time to onset of limiting angina during treadmill exercise in men with erectile dysfunction and stable chronic angina: effect of sildenafil citrate (abst). Circulation 2001; 104(SupplIl):601–602.

    Google Scholar 

  76. Hebert K, Lee M, Ferguson T. Is sildenafil (Viagra’) safe and effective for the treatment of erectile dysfunction in patients with heart failure? (abst). Circulation 2000;102(Suppl II):413.

    Google Scholar 

  77. Hebert KA, Arcement LM, Ewing T, et al. Assessment of erectile dysfunction in a multidisciplinary heart failure program (abst). J Am Coll Cardiol 2001;37 (Suppl A):212A.

    Article  Google Scholar 

  78. Bocchi EA, Guimaraes G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure. Circulation 2002;106:1097–1103.

    Article  PubMed  Google Scholar 

  79. Parums DV, Charlton RG, Johnson N, et al. Immunohistochemical (IHC), in situ hybridisation (ISH) and biochemical characterisation of phosphodiesterase type 5 (PDE5) in normal and ischaemic human cardiac tissue (PDE5). Eur Heart J 2000; 21:616.

    Google Scholar 

  80. Gomez-Sanchez MA, de la Calzeda CS, Lazaro M, et al. Beneficial acute hemodynamic effects of sublingual sildenafil in refractory pulmonary hypertension due to chronic heart failure. Presented at: Heart Failure Update; June 8–11, 2002; Oslo, Norway.

    Google Scholar 

  81. Lepore J, Pereira N, Maroo A, et al. Sildenafil is a pulmonary vasodilator which augments and prolongs vasodilation by inhaled nitric oxide in patients with pulmonary hypertension. Circulation 1999;100:I-240.

    Google Scholar 

  82. Veyssier-Belot C, Cacoub P. Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. Cardiovasc Res 1999;44:274–282.

    Article  PubMed  CAS  Google Scholar 

  83. Jackson G, Chambers J. Sildenafil for primary pulmonary hypertension: short and long-term symptomatic benefit [case report]. Int J Clin Pract 2002;55:397–398.

    Google Scholar 

  84. Hoeper MM, Galie N, Simonneau G, et al. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:1209–1216.

    Article  PubMed  Google Scholar 

  85. Pauvert O, Salvail D, Rousseau E, et al. Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery. Biochem Pharmacol 2002;63:1763–1772.

    Article  PubMed  CAS  Google Scholar 

  86. Clarke WR, Uezono S, Chambers A, et al. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm Pharmacol 1994;7:81–89.

    Article  PubMed  CAS  Google Scholar 

  87. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001;104:424–428.

    Article  PubMed  CAS  Google Scholar 

  88. Schermuly RT, Weissmann N, Enke B, et al. Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication. Am J Respir Cell Mol Biol 2001;25:219–225.

    PubMed  CAS  Google Scholar 

  89. Dukarm RC, Morin FC 3rd, Russell JA, et al. Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension. Pediatr Res 1998;44:831–837.

    Article  PubMed  CAS  Google Scholar 

  90. Braner DA, Fineman JR, Chang R, et al. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol 1993;264:H252–H258.

    PubMed  CAS  Google Scholar 

  91. Ichinose F, Adrie C, Hurford WE, et al. Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology 1998;88:410–416.

    Article  PubMed  CAS  Google Scholar 

  92. Ichinose F, Erana-Garcia J, Hromi J, et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001;29:1000–1005.

    Article  PubMed  CAS  Google Scholar 

  93. Nagamine J, Hill LL, Pearl RG. Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension. Crit Care Med 2000;28: 2420–2424.

    Article  PubMed  CAS  Google Scholar 

  94. Weimann J, Ullrich R, Hromi J, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000;92: 1702–1712.

    Article  PubMed  CAS  Google Scholar 

  95. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002;165:1098–1102.

    PubMed  Google Scholar 

  96. Fullerton DA, Jaggers J, Piedalue F, et al. Effective control of refractory pulmonary hypertension after cardiac operations. J Thorac Cardiovasc Surg 1997; 113:363–368; discussion 368–370.

    Article  PubMed  CAS  Google Scholar 

  97. Ziegler JW, Ivy DD, Wiggins JW, et al. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am J Respir Crit Care Med 1998;158:1388–1395.

    PubMed  CAS  Google Scholar 

  98. Klings ES, Farber HW. Current management of primary pulmonary hypertension. Drugs 2001;61:1945–1956.

    Article  PubMed  CAS  Google Scholar 

  99. Patel RV, Karsh J, Jones G. Sildenafil for the treatment of end stage pulmonary hypertension. Presented at: 97th International Conference of the American Thoracic Society; May 18–23, 2001; San Francisco, CA.

    Google Scholar 

  100. Pritzker M, Dorman W, Caperton E. The use of sildenafil (Viagra) for the treatment of pulmonary hypertension associated with scleroderma. Arthritis Rheum 2001;44(Suppl 9):S131(abstract 471).

    Google Scholar 

  101. Schumacher YO, Zdebik A, Huonker M, et al. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001;15:1747–1748.

    Article  PubMed  CAS  Google Scholar 

  102. Bigatello LM, Hess D, Dennehy KC, et al. Sildenafil can increase the response to inhaled nitric oxide. Anesthesiology 2000;92:1827–1829.

    Article  PubMed  CAS  Google Scholar 

  103. Li J, Schulze-Neick I, Petros A, et al. Intravenous sildenafil and pulmonary vascular resistance in children with congenital heart disease. Presented at: 3rd World Congress of Pediatric Cardiology and Cardiac Surgery; May 31, 2001; Toronto, Canada.

    Google Scholar 

  104. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105:2398–2403.

    Article  PubMed  CAS  Google Scholar 

  105. Schulze-Neick I, Dietz P, Stiller B, et al. Sildenafil lowers pulmonary vascular resistance in children after heart surgery (abst). Eur Heart J 2002;23:490.

    Article  Google Scholar 

  106. Mikhail G, Prasad S, Rogers P, et al. Clinical and haemodynamic effects of sildenafil in pulmonary arterial hypertension [abstract]. Presented at: American Heart Association; November 17–20, 2002, 2002; Chicago, IL.

    Google Scholar 

  107. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104: 1218–1222.

    Article  PubMed  CAS  Google Scholar 

  108. Abrams DJR, Gatzoulis MA, Magee AG. Oral sildenafil-a novel therapy for primary pulmonary hypertension. Presented at: 3rd World Congress of Pediatric Cardiology and Cardiac Surgery; May 29, 2001; Toronto, Canada.

    Google Scholar 

  109. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension [Letter]. N Engl J Med 2000;343:1342.

    Article  PubMed  CAS  Google Scholar 

  110. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515–522.

    PubMed  CAS  Google Scholar 

  111. Erickson S, Reyes J, Bohn D, et al. Sildenafil (Viagra) in childhood and neonatal pulmonary hypertension. J Am Coll Cardiol 2002, in press.

    Google Scholar 

  112. Siddons TE, Asif M, Armstrong I, et al. Long term effects of oral sildenafil (Viagra®) on haemodynamics and exercise tolerance in patients with pulmonary hypertension. Am J Resp Crit Care 2001;A541.

    Google Scholar 

  113. Zimmermann AT, Calvert AF, Veitch EM. Sildenafil improves right-ventricular parameters and quality of life in primary pulmonary hypertension [letter]. Intern Med J 2002;32:424–426.

    Article  PubMed  CAS  Google Scholar 

  114. Wheeler EA. Sildenafil-a replacement for inhaled nitric oxide in cardiac surgery? (abst). Anesth Analg 2002;94(Suppl 2):l.

    Google Scholar 

  115. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999;91:307–310.

    Article  PubMed  CAS  Google Scholar 

  116. Mychaskiw G, Sachdev V, Heath BJ. Sildenafil (Viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device. J Clin Anesth 2001;13:218–220.

    Article  PubMed  CAS  Google Scholar 

  117. Ivy DD, Kinsella JP, Ziegler JW, et al. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 1998;115:875–882.

    Article  PubMed  CAS  Google Scholar 

  118. Lepor JJ, Maroo A, Ginns L. Sildenafil is a pulmonary vasodilator which augments and prolongs vasodilation by inhaled nitric oxide in patients with pulmonary hypertension. Presented at: 7th World Congress on Heart Failure: Mechanisms & Management; July 9–12, 2000; Vancouver, British Columbia.

    Google Scholar 

Download references

Authors
  1. Michael Sweeney MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard L. Siegel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    Robert A. Kloner MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Sweeney, M., Siegel, R.L. (2004). Potential Cardiac Applications of Phosphodiesterase Type-5 Inhibition. In: Kloner, R.A. (eds) Heart Disease and Erectile Dysfunction. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-748-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-748-2_13

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9849-3

  • Online ISBN: 978-1-59259-748-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation